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Asymmetric Dimethylarginine: Clinical Applications
in Pediatric Medicine
You-Lin Tain,* Li-Tung Huang
Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase (NOS).
Growing evidence indicates that ADMA plays an important role in the initiation and progression of a variety
of adulthood diseases, especially in the cardiovascular and renal systems. However, the study of ADMA in
pediatric diseases has just begun. This review provides an overview of potential clinical applications of
ADMA in pediatric practice, with an emphasis on the following areas: the biochemistry and pathophysiology
of ADMA; clinical ramifications of elevated ADMA levels in pediatric population; age-related normal refer-
ence ranges of ADMA; methodology for measuring ADMA; current and potential agents to reduce ADMA;
and the problems that must be addressed before use of ADMA in pediatric medicine. ADMA will soon be
available for use as a biomarker and therapeutic target in the pediatric population.
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What is Asymmetric Dimethylarginine?
Asymmetric dimethylarginine (ADMA) is a natu-
rally occurring amino acid that can inhibit the
activity of nitric oxide synthase (NOS) to reduce
NO production (Figure).1 Protein-incorporated
ADMA is formed by post-translational methyla-
tion, in which two methyl groups are placed on
one of the terminal nitrogen atoms of the guani-
dino group of arginine in proteins, by the pro-
tein arginine methyltransferases (PRMTs).2 Free
ADMA is then released after proteolysis. Two
other derivatives that are methylated by PRMTs
are symmetric dimethylarginine (SDMA) and
monomethylarginine (MMA). Peptidylarginine
deaminases can block methylation on the argi-
nine residue within proteins by converting the
arginine to citrulline.3 However, peptidylarginine
deaminases are not demethylases. The first argi-
nine demethylase, JMJD6, was recently identified
that can demethylate both protein-incorporated
ADMA and SDMA.4 A healthy adult produces
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300 μmol (~60 mg) of ADMA per day.5 The other
two derivatives are produced at 20–50% of the
amount of ADMA.2 Free ADMA can be trans-
ported in or out of cells via the cationic amino
acid transporter family.6 Thus, excess circulating
ADMA can be transported to major organs for
ADMA degradation, such as the kidney and liver.
Besides ADMA, other methylarginines also share
a common transport process with L-arginine.
Approximately 20% of ADMA is excreted by the
kidneys into the urine, whereas 80% of ADMA 
is metabolized by the enzyme dimethylarginine 
dimethylaminohydrolase (DDAH) to citrulline
and dimethylamine.6 The biochemical pathways
related to ADMA are illustrated in the Figure.
Why is the Study of ADMA Interesting?
ADMA is an endogenous NOS inhibitor. By in-
hibiting NO bioavailability, ADMA causes en-
dothelial dysfunction, vasoconstriction, blood
pressure elevation, atherosclerosis, and kidney
disease progression.7–11 A high prevalence of ele-
vated plasma ADMA levels is observed in adults
with hypercholesterolemia, hypertension, chronic
kidney disease, diabetes mellitus, peripheral arte-
rial disease, coronary artery disease, preeclampsia,
heart failure, liver disease, stroke, and many
other clinical disorders. The pathophysiological 
evidence of ADMA in these disorders is not 
reviewed here because this has been reviewed
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Figure. Protein arginine methylation is performed by a family of enzymes named protein arginine methyltransferases
(PRMTs), which methylate protein-incorporated L-arginine residues to generate protein-incorporated monomethylargi-
nine (MMA). Type I PRMTs next convert MMA to asymmetric dimethylarginine (ADMA), and type II PRMTs generate
symmetric dimethylarginine (SDMA). At the protein level, protein-incorporated L-arginine residues can be converted to
citrulline by peptidylarginine deaminases, thereby blocking methylation on the arginine residue. Upon proteolytic cleav-
age of arginine-methylated proteins, free MMA, ADMA, or SDMA is generated and released into the cytoplasm. Free 
L-arginine can be metabolized by nitric oxide synthase to NO and L-citrulline. By contrast, MMA and ADMA, but not
SDMA, act as endogenous nitric oxide synthase inhibitors. In addition to L-arginine, free methylarginines can also be re-
leased into the extracellular space by cationic amino acid transporter and transported to other organs or renally excreted.
ADMA, but not SDMA, can be converted to L-citrulline and dimethylamine by dimethylarginine dimethylaminohydrolase.
The structure of ADMA is shown in the upper middle portion of the figure. PAD = peptidylarginine deaminase; NOS = nitric
oxide synthase; CAT = cationic amino acid transporter; DDAH = dimethylarginine dimethylaminohydrolase.
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previously.5,9,11–15 The primary focus of this re-
view is to summarize and discuss recent clinical
and experimental evidence in which the possible
role of ADMA as a biomarker and therapeutic target
in the pediatric population has been assessed.
Is ADMA an Important Risk Marker in
Pediatric Diseases?
Prospective clinical studies have indicated a role
for ADMA as a novel cardiovascular risk factor in
various groups of adults, such as patients with
hemodialysis,16 critically ill patients in the inten-
sive care unit,17 and patients with coronary ar-
tery disease.18 In these studies, patients whose
ADMA levels were within the highest quartile at
the beginning of the study had 3–17-fold in-
creased mortality compared with those with
ADMA levels in the lowest quartile. Furthermore,
a 0.13-μM increase in ADMA was associated with
a 21% increase in mortality risk in the general
population.19 Thus, ADMA has been considered
as a predictor of cardiovascular disease events and
death in the adult population.
The list of clinical conditions in which elevated
ADMA levels are found in the pediatric population
continues to grow (Table).20–30 Consistent with
the emergence of ADMA as a risk marker of car-
diovascular disease in adults,11 increased ADMA
levels have been found in children and adolescents
with endothelial dysfunction, including hyper-
tension,20 hypercholesterolemia,28 chronic kidney
disease,25 and diabetes mellitus.23 Unlike prospec-
tive data that indicate a direct and independent
association between ADMA and cardiovascular
endpoints in adult patients with different cardio-
vascular diseases,12 pediatric studies have been
limited by inadequate power and small sample
size. Atherosclerosis manifests usually from mid-
dle age through a long preclinical stage, whereas
endothelial dysfunction begins in childhood;
therefore, the outcomes of ultimate importance
in adults (e.g. death or cardiovascular events)
rarely occur during childhood. It is noteworthy
that ADMA levels are elevated in children with
congenital urea cycle disorders29 and in preterm
infants with mechanical ventilation.24 Instead of
studying disorders that are characterized by ele-
vated ADMA levels in adulthood, pediatricians
might pay more attention to those diseases that
are common in children and adolescents.
Measurement of ADMA in Pediatric
Populations
Heterogeneity is an unavoidable feature in pedi-
atric studies. From birth to adolescence, numerous
physiological changes occur in the body; for 
Table. Clinical conditions with elevated plasma ADMA levels in pediatric populations
Condition % increase References
from controls
Hypertension 128 Goonasekera et al, 1997 [20]
Congenital heart disease with pulmonary hypertension 160 Gorenflo et al, 2001 [21]
Preterm infant 35 Mittermayer et al, 2006 [22]
Type 1 diabetes mellitus 50 Altinova et al, 2007 [23]
Preterm infant with mechanical ventilation 12 Richir et al, 2008 [24]
Chronic kidney disease 38–200 Brooks et al, 2008 [25]
Focal and segmental glomerulosclerosis 25 Lucke et al, 2008 [26]
Arterial wall thickness ND Ayer et al, 2009 [27]
Familial hypercholesterolemia 22 Jehlicka et al, 2009 [28]
Argininosuccinate synthetase deficiency 177 Nagasaca et al, 2009 [29]
Congenital portosystemic venous shunt 30 Nagasaca et al, 2010 [30]
ND = not determined.
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example, kidney function increases substantially
during the first 2 years of life. Given that 20% of
ADMA is excreted in the urine and renal function
is different from birth to adolescence, the ADMA
level is greatly variable in pediatric populations
due to the broad age range. In adults, plasma
ADMA concentrations tend to increase with age,
and the mean concentration for a healthy adult
is between 0.4 μM and 0.6 μM.31 The distribution
of plasma ADMA levels among healthy, older
adults (age > 60 years) ranges from 0.47 μM to
0.85 μM; ADMA levels vary nearly twofold in the
geriatric population.32 In addition, the sex differ-
ence in ADMA concentrations is small in hu-
mans.31,33 By contrast, only a few of studies have
reported ADMA levels in neonates. Vida et al
have demonstrated that venous cord blood ADMA
levels are markedly elevated (∼1.06 μM) and fall
significantly close to the normal adult levels by
postnatal day 2 (∼0.66 μM).34 In preterm infants,
plasma ADMA level remains unchanged during
the first week of life but increases by the fourth
week, from 0.66 μM to 0.95 μM.35 During child-
hood, ADMA levels are higher than those in adults
and diminish from birth until around 25 years of
age, with a mean decrease of 15 nM per year.33,36
Although ADMA levels are highest in neonatal
and geriatric populations, it remains to be deter-
mined whether the U-shaped relationship between
normal ADMA levels and age can be attributed
to renal function.
Thus far, analytical techniques for the quanti-
tative determination of ADMA include high-
performance liquid chromatography (HPLC),
gas chromatography–mass spectrometry (MS), gas
chromatography–tandem MS, liquid chromatog-
raphy (LC)–MS, LC–tandem MS, and enzyme-
linked immunosorbent assay. HPLC-based
methods are the most widely used techniques for
measuring ADMA in biological fluids such as
plasma, urine, and tissue homogenate. However,
enzyme-linked immunosorbent assay is not as
reliable as currently available and validated HPLC-
and LC–MS-based methods for detecting circu-
lating ADMA.33 Differences observed among 
different studies for reported plasma (or serum)
ADMA levels in healthy adults might have been
due to age,31 race,32 body mass,32 or methodol-
ogy.31 However, whether these factors influence
ADMA levels in pediatric populations needs fur-
ther investigation.
Intracellular ADMA in Experimental
Disease Models
At normal ranges of extracellular L-arginine and
ADMA concentration, intracellular NOS is well
saturated with its substrate L-arginine, which re-
sults in physiological production of NO. In the
presence of pathological concentrations of ADMA
but physiological concentrations of L-arginine,
NOS activity decreases, which causes decreased
NO production. Cellular ADMA levels can be
5–20-fold higher than those in the plasma and
exist in a range that can inhibit NOS.6 Under such
conditions, the addition of exogenous L-arginine
displaces intracellular ADMA and restores the
physiological L-arginine to ADMA ratio to a level
that preserves adequate NO production. Therefore,
the state of activation or inhibition of NOS de-
pends on the local intracellular concentration of
L-arginine and ADMA, or the L-arginine/ADMA
ratio. Although plasma ADMA levels increase in
many patients with different disorders, intracel-
lular ADMA levels have not been well studied
under these circumstances. It is difficult to obtain
tissue samples from humans; therefore, animal
models might prove to be advantageous for
studying intracellular ADMA regulation.
There is very limited information regarding
intracellular ADMA levels in young diseased ani-
mal models. We have found recently that plasma,
hepatic, and renal ADMA levels are increased in
young rats 2 weeks after bile-duct ligation;37 a com-
monly used cholestatic liver disease model. The
increase in circulating ADMA is probably caused
by increased synthesis of ADMA (by increased
PRMT1 abundance) in the liver. Nevertheless,
the metabolism of ADMA appears unaltered
(represented by unaltered DDAH expression/
activity) in the damaged liver. By contrast, the
Y.L. Tain, L.T. Huang
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decreased renal DDAH activity suggests that the
kidneys are unable to metabolize excess ADMA.
Unlike in the liver and kidneys, ADMA level in
the cerebral cortex of young bile duct ligation
rats is not changed.38 These findings highlight
the importance of studying tissue instead of
plasma ADMA levels because the change in plasma
ADMA levels is not the equivalent of intracellu-
lar ADMA levels in different tissues. In addition,
intracellular ADMA can be regulated differentially
in different tissues in the same disease model.
In spontaneously hypertensive rats, a com-
monly employed experimental model of hyper-
tension, plasma ADMA level is not significantly
elevated, but renal ADMA concentration is higher
than in control Wistar–Kyoto rats at 4 weeks of
age.39 With the development of hypertension, the
plasma ADMA level is elevated in spontaneously
hypertensive rats at 12 and 24 weeks of age, which
suggests that the accumulation of ADMA in 
the kidneys that precedes elevation of blood pres-
sure might play a role in the development of 
hypertension.
In addition, the progressive increase in ADMA
levels in preterm infants suggests that ADMA par-
ticipates in developmental programming of
chronic adult diseases.30 In the offspring from a
50% maternal caloric restriction (CR) rat model,
we found that plasma ADMA levels were elevated
nearly 30% in the CR group, whereas the renal
ADMA increases were not significant.40 Renal
DDAH (ADMA-metabolizing enzyme) activity was
significantly increased in the CR group. Thus, it
is presumed that plasma ADMA increases observed
with CR might be caused by excessive synthesis or
decreased metabolism of ADMA in extra-renal tis-
sues. However, as a major organ of ADMA me-
tabolism, the kidney has increased DDAH activity
to metabolize excess circulating ADMA and main-
tain a steady ADMA concentration. These findings
highlight that the regulation of intracellular ADMA
is complex, and the ability to maintain steady in-
tracellular ADMA levels might protect the tissue
against ADMA-induced damage.
Conclusively, our data implicate the impor-
tance of ADMA in young diseased animal models
with different insults, such as liver, kidney, and
cardiovascular injury.37–40 Alternatively, it is note-
worthy that studying systemic and tissue ADMA
levels simultaneously is required to elucidate the
relative importance of different mechanisms that
regulate ADMA homeostasis.
Thus far, considerably less attention has been
paid to tissue than plasma ADMA levels in clini-
cal practice, largely because of the lack of an ideal
methodology. In addition, even though techniques
used to assess tissue DDAH activity and expression
in experimental studies are well established,33,37,41
clinical application is restricted due to the limited
availability of samples. However, recent studies
have suggested that the plasma L-arginine/
ADMA5 and urine ADMA/DMA (the metabolite
of ADMA by DDAH) ratios might provide addi-
tional useful clinical information.42
How to Treat Elevated ADMA Levels?
To date, a specific ADMA-lowering agent remains
unavailable. Clinical studies have reported that
treatment with metformin, oral contraceptives,
angiotensin-converting enzyme inhibitors, an-
giotensin receptor blockers, fenofibrate, folic
acid, and α-lipoic acid can lower plasma ADMA
levels.43–52 Doubts remain whether the 10–24%
decreases in plasma ADMA levels induced by these
agents in different diseases are beneficial. Given
that intracellular ADMA levels are mainly regu-
lated by PRMT and DDAH, specific PRMT in-
hibitors or DDAH agonists might become novel
therapeutic strategies.
First, because of the high degree of sequence
conservation across the PRMT family throughout
evolution, creation of specific PRMT inhibitors is
difficult.2 In addition, because of the involvement
of PRMT in complex cellular physiology, PRMT
inhibition might be fraught with unwanted side
effects. However, a number of effective PRMT in-
hibitors await further experimental evaluation.53
Second, recent advances in understanding the
regulation of DDAH enzymes might lead to sig-
nificant new therapeutic targets.54 Experimental
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studies have indicated that pravastatin, aminogua-
nidine, pioglitazone, probucol, farnesoid X recep-
tor agonists, vitamin E, and melatonin can increase
the activity and/or expression of DDAH, and
thereby reduce ADMA levels.37,55–60 It needs to be
further evaluated whether there are inter-species
differences in the renal handling of ADMA and
whether ADMA-lowering therapy in experimental
animals can be translated successfully to humans,
especially in pediatric populations.
Are We Ready for ADMA in Pediatric
Practice?
ADMA was first isolated and identified from
human urine in 1970.61 Vallance et al first re-
ported that ADMA acts as an endogenous NOS
inhibitor in 1992,1 and since then, ADMA has re-
ceived considerable interest as a research topic.62
Circumstantial evidence suggests that ADMA plays
a crucial role in the initiation and progression of
various diseases, especially in the cardiovascular
and renal systems in adults.8,9,54 However, the
study of ADMA in pediatric diseases remains a
burgeoning field.
The major blocks to future clinical applica-
tion of ADMA in pediatric practice are as follows:
(1) plasma ADMA measurements in patients are
not yet performed on a routine basis; (2) large,
prospective, multicenter collaborations are re-
quired to conduct meaningful clinical research
studies in children to prove that ADMA is a novel
risk factor in pediatric disorders; (3) measure-
ment of ADMA for age- or size-related hetero-
geneity needs normalization; (4) indices that
represent intracellular ADMA levels from experi-
mental models are required for clinical transla-
tion; and (5) specific ADMA-lowering agents still
require investigation.
In conclusion, this review provides an overview
of clinical applications of ADMA, with an empha-
sis on pediatric populations: (1) it discusses the
biochemistry and pathophysiology of ADMA;
(2) it presents a list of pediatric diseases with 
elevated ADMA levels; (3) it presents age-related
normal reference ranges of ADMA and the
methodology for measuring ADMA; (4) it dis-
cusses the ever-accumulating body of data link-
ing agents to the reduction of ADMA levels, and
new and interesting data on lowering ADMA in
experimental models; and (5) it indicates prob-
lems that must be addressed before ADMA can
be used in pediatric medicine.
Basic and clinical research performed during
the last 20 years has implicated ADMA as a novel
cardiovascular risk factor, diagnostic marker, and
therapeutic target in adult populations. Additional
studies exploring its role as a causal factor and as
a target for drug development are warranted, es-
pecially in pediatric diseases.
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